Nearmedic, a Russian pharmaceutical, biotechnological, and medical company, reported on September 17, 2020 that it plans to begin production of a new line of Martiflex medical products for bone regeneration, including Matriflex APATITE, Matriflex MATRIX, and Matriflex COLLAGEN.

Production is to start at the BioPHARMAHOLDING, LLC site, which is part of the Nearmedic Group. All of the above products are based on the company’s patented original developments.

The efficacy and safety of Matriflex products have been demonstrated in pre-registration tests carried out in accordance with the best international standards and practices. The results of these studies were recently published in Materials, a leading Swiss journal.

The paper published investigated the efficacy of bone recovery using various natural biomaterials: purified hydroxyapatite, demineralized bone matrix, and purified bone collagen. It also offered a comparison with the commercially available medical device Spirit Bio-oss and bone autografts. A standard validated model of a critical skull arch defect in rats was used. Purified hydroxyapatite (Matriflex APATITE) and demineralized bovine bone matrix (Matriflex MATRIX) have been shown to have excellent recovery capabilities similar to autografts and the commercially available Geistlich Bio-oss. At the same time, purified bone collagen (Matriflex collagen) showed a higher rate of bone recovery and thus the highest regeneration potential.

“The launch of a new domestic line of bone preservation medical products solves two important challenges. First, it envisages the expansion of the use of these products in Russia, as a result of the high competitiveness of Matriflex products and their availability to patients and clinics. Second, it opens up prospects for import substitution and entry into foreign markets, in light of the high efficiency and safety of these products, which are comparable to the best products currently available. The most important step in this direction is our firm substantiation of the results announced with the publication of preclinical and clinical research materials in highly-rated international journals,” said Alexey Veremeev, head of the medical devices division at the Nearmedic Group.

The first product of the series, the Matriflex APATITE purified bone hydroxyapatite, is in the process of obtaining a registration certificate.